/

Other

/

Incyte

Incyte

Incyte

Verified Nov 2026

Other

·

United States flag

Wilmington, Delaware

·

Since 1991

Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991. Employing approximately 2,500 people with estimated revenue of $5–10 billion, it develops small-molecule therapeutics for oncology, hematology, and inflammatory diseases. The company expanded its hematology portfolio through a 2026 acquisition and collaborates with partners including Novartis and Eli Lilly on approved products such as Jakafi for myelofibrosis.

Incyte

Verified Nov 2026

AT A GLANCE

Founded

1991

Headquarters

United States flag

Wilmington, Delaware

Employees

1,000-5,000

Ownership

Incyte at a glance

Revenue

$5-10B

Est. band

Employees

1,000-5,000

Founded

1991

Headquarters

Wilmington, Delaware

Certifications

ISO 14001 · ISO 45001 · ISO 50001

Import activity

4

Industries

Automotive

Electric Vehicles

Medical

Sourcing and import activity

From US customs bill-of-lading records

US sea imports

4

Named foreign suppliers

3

Top origins

Germany · Belgium

Chart of the supplier's US import shipment volume trend over time

Shared foreign counterparties do not establish that these companies buy from Incyte.

What this tells a buyer

Incyte received 161 documented shipments from three major suppliers: Konvekta in Switzerland (103 shipments), Siegfried in Belgium (53 shipments), and Becomix A Berents in Germany (5 shipments).

The company holds ISO 14001 (environmental management), ISO 45001 (occupational health and safety), and ISO 50001 (energy management) certifications.

In November 2026, Incyte entered a clinical collaboration with Natera on a Phase II interventional study in colorectal cancer, and expanded its molecular AI drug discovery partnership with Genesis.

Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026

STABILITY SIGNALS

Established & active

35 years in operation (founded 1991).

4 US import shipments on record.

Holds ISO 14001, ISO 45001, ISO 50001 certification(s) per public sources.

Overview

Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991. Employing approximately 2,500 people with estimated revenue of $5–10 billion, it develops small-molecule therapeutics for oncology, hematology, and inflammatory diseases. The company expanded its hematology portfolio through a 2026 acquisition and collaborates with partners including Novartis and Eli Lilly on approved products such as Jakafi for myelofibrosis.

At a glance

Attribute

Detail

Founded

1991

Headquarters

Wilmington, Delaware

Employees

1,000-5,000

Revenue

$5-10B (estimated)

Certifications

ISO 14001 · ISO 45001 · ISO 50001

What Incyte makes

The company holds ISO 14001 (environmental management), ISO 45001 (occupational health and safety), and ISO 50001 (energy management) certifications.

Certifications

Incyte is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:

Trade and customs footprint

Incyte received 161 documented shipments from three major suppliers: Konvekta in Switzerland (103 shipments), Siegfried in Belgium (53 shipments), and Becomix A Berents in Germany (5 shipments). US customs bill-of-lading records list 4 inbound shipments across 3 foreign suppliers, with top origins including Germany · Belgium.

Latest developments

Company details

In November 2026, Incyte entered a clinical collaboration with Natera on a Phase II interventional study in colorectal cancer, and expanded its molecular AI drug discovery partnership with Genesis. Incyte was founded in 1991, has an estimated 1,000-5,000 employees, and is headquartered in Wilmington, Delaware. On the LightSource stability read it is rated "Established & active": 35 years in operation (founded 1991). 4 US import shipments on record. Holds ISO 14001, ISO 45001, ISO 50001 certification(s) per public sources.

Frequently asked questions

What does Incyte do?

Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991. Employing approximately 2,500 people with estimated revenue of $5–10 billion, it develops small-molecule therapeutics for oncology, hematology, and inflammatory diseases. The company expanded its hematology portfolio through a 2026 acquisition and collaborates with partners including Novartis and Eli Lilly on approved products such as Jakafi for myelofibrosis.

Where is Incyte headquartered?

Incyte is headquartered in Wilmington, Delaware (1801 Augustine Cut Off, Wilmington, Delaware, 19803).

When was Incyte founded?

Incyte was founded in 1991.

How big is Incyte?

Incyte has an estimated 1,000-5,000 employees, with revenue in the $5-10B range (estimated).

What certifications does Incyte hold?

Incyte lists ISO 14001 · ISO 45001 · ISO 50001 on its website. Confirm the certified scope for the specific plant producing your part.

Does Incyte import from overseas suppliers?

US customs bill-of-lading records show 4 inbound shipments for Incyte, with top origins including Germany · Belgium.

Related suppliers

Explore other suppliers in the LightSource directory:

Last verified Nov 2026. Is this your company? Request a correction.

Location & contact

Wilmington, Delaware (HQ)Headquarters · United States
Wilmington, Delaware (HQ)1801 Augustine Cut Off, Wilmington, Delaware, 19803, United StatesHeadquarters

Phone

'+1 302-498-6700

Certification

ISO 14001 · ISO 45001 · ISO 50001

Evaluating suppliers like these?

This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.